SynAct Pharma AB (OSTO:SYNACT) Cash And Cash Equivalents : kr62.40 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Cash And Cash Equivalents?

SynAct Pharma AB's quarterly cash and cash equivalents declined from Jun. 2023 (kr44.42 Mil) to Sep. 2023 (kr28.88 Mil) but then increased from Sep. 2023 (kr28.88 Mil) to Dec. 2023 (kr62.40 Mil).

SynAct Pharma AB's annual cash and cash equivalents increased from Dec. 2021 (kr24.00 Mil) to Dec. 2022 (kr108.25 Mil) but then declined from Dec. 2022 (kr108.25 Mil) to Dec. 2023 (kr62.40 Mil).

SynAct Pharma AB Cash And Cash Equivalents Historical Data

The historical data trend for SynAct Pharma AB's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB Cash And Cash Equivalents Chart

SynAct Pharma AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

3.51

14.55

24.00

108.25

62.40

SynAct Pharma AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															108.25	78.21	44.42	28.88	62.40

SynAct Pharma AB Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

SynAct Pharma AB (OSTO:SYNACT) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

SynAct Pharma AB Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

SynAct Pharma AB (OSTO:SYNACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

8F8:Germany

Address

Sheelevagen 2, Lund, SWE, 223 81

Website

https://www.synactpharma.se

SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines